Endokrin kombinierte Therapie des metastasierten Mammakarzinoms – Lebensqualität und Lebensverlängerung durch zielgerichtete Tumortherapie

Im Zentrum der medikamentösen Systemtherapie des metastasierten Mammakarzinoms steht neben der Kontrolle der tumorassoziierten Symptome und Verlängerung des Überlebens auch die individuelle Lebensqualität der Patientinnen. Daher ist die endokrine Therapie mit ihrem günstigeren Nebenwirkungsprofil im Vergleich zur Chemotherapie die Erstlinientherapie der Wahl bei Hormonrezeptorpositivität. Die antihormonelle Therapie kann als Monotherapie oder in Kombination mit zielgerichteten Substanzen eingesetzt werden.

Schlüsselwörter

Hormonrezeptorpositives metastasiertes Mammakarzinom - Endokrine Therapie - CDK4/6i - PI3K/AKT/mTOR - Signaltransduktionsweg - Biomarker

• Literatur

• 1 RKI. Robert Koch Institut (Hrsg.). Brustkrebs (Mammakarzinom) Datenbankabfrage Das ZfKD File. Zent für Krebsregisterdaten Krebs Deutschl für 2015/2016. 2016 https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html
• 2 Setiawan VW, Monroe KR, Wilkens LR. et al. Breast cancer risk factors defined by estrogen and progesterone receptor status. Am J Epidemiol 2009; 169: 1251-1259
• 3 Schrijver WAME, Suijkerbuijk KPM, Van Gils CH. et al. Receptor conversion in distant breast cancer metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst 2018; 110: 568-580
• 4 Hammond MEH, Hayes DF, Dowsett M. et al. American Society of Clinical oncology/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: 907-922
• 5 Coates AS, Winer EP, Goldhirsch A. et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-1546
• 6 Prabhu JS, Korlimarla A, Desai K. et al. A majority of low (1–10%) er positive breast cancers behave like hormone receptor negative tumors. J Cancer 2014; 5: 156-165
• 7 Onkologie L. Leitlinienprogramm Onkologie: S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.0. 2020 http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
• 8 Pfeiler G. Systemic Treatment in Premenopausal Patients with Breast Cancer. Breast Care 2015; 10: 305-306
• 9 Portman N, Alexandrou S, Carson E. et al. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer 2019; 26: R15-R30
• 10 Thill, Untch. AGO Guideline 2020: Diagnostik und Therapie früher und fortgeschrittener Mammakarzinoms-Endokrine und zielgerichtete Therapie des metastasierten Mammakarzinoms. 2020 Accessed February 14, 2023 at: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2020/Alle_aktuellen_Empfehlungen_2020.pdf
• 11 Cardoso F, Senkus E, Costa A. et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 2018; 29: 1634-1657
• 12 Robson M, Im SA, Senkus E. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377: 523-533
• 13 Gibson L, Lawrence D, Dawson C. et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009;
• 14 Buzdar AU, Robertson JFR, Eiermann W. et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002; 95: 2006-2016
• 15 Howell A, Robertson JFR, Abram P. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-1613
• 16 Robertson JFR, Bondarenko IM, Trishkina E. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016; 388: 2997-3005
• 17 Johnston SRD, Harbeck N, Hegg R. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR 1, HER2 2 , abstract. J Clin Oncol 2020; 38 (34) 3987-3998
• 18 Yardley DA, Noguchi S, Pritchard KI. et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013; 30: 870-884
• 19 Kornblum N, Zhao F, Manola J. et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE. J Clin Oncol 2018; 36: 1556-1563
• 20 Piccart M, Hortobagyi GN, Campone M. et al. Everolimus plus exemestane for hormonereceptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2. Ann Oncol 2014; 25: 2357-2362
• 21 Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and Pi3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014; 7: 203-215
• 22 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936
• 23 Finn RS, Rugo HS, Dieras VC. et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. J Clin Oncol 2022; 40: LBA1003-LBA1003
• 24 Slamon DJ, Neven P, Chia S. et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 2021; 32: 1015-1024
• 25 Lu YS, Im SA, Colleoni M. et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res 2022; 28: 851-859
• 26 Sledge GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy – MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6: 116-124
• 27 Johnston S, Martin M, Di Leo A. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. npj Breast Cancer 2019; 5: 1-8
• 28 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
• 29 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
• 30 Martín M, Zielinski C, Ruíz-Borrego M. et al. Abstract GS2–07: Results from PEARL study (GEICAM/2013–02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor recept. Cancer Res 2020; 80: GS2-07
• 31 Yeon Hee Park, Tae-Yong Kim, Gun Min Kim. et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15–10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019; 20: 1750-1759
• 32 Kalinsky K, Accordino MK, Chiuzan C. et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. J Clin Oncol 2022; 40: LBA1004-LBA1004
• 33 Anderson EJ, Mollon LE, Dean JL. et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. Int J Breast Cancer 2020; 2020
• 34 André F, Ciruelos E, Rubovszky G. et al. Alpelisib for PIK3CA -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
• 35 André F, Ciruelos EM, Juric D. et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32: 208-217
• 36 Novartis. Piqray (Alpelisib). 2021 Accessed July 20, 2021 at: https://www.novartis.de/arzneimittel-produkte/piqray-informationen-zur-risikominimierung
• 37 Rugo HS, Lerebours F, Ciruelos E. et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA- mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 i. J Clin Oncol 2020; 38: 1006-1006